Bobby Soni
Chief Business Officer @ BioInnovation Institute
London, United Kingdom
Bobby Soni is a convertible note investor at BioInnovation Institute in London focused on Biotechnology and Medical. Bobby joined Novo A/S in January 2009 as Principal in Novo Seeds.Bobby obtained his BS in Biochemistry from the University of Rochester in 1992 and his PhD degree in Biology from the University of Virginia in 1998. His PhD research was primarily conducted at Imperial College of Science, London and was published in leading scientificjournals.Prior to joining Novo Seeds, Bobby was Discovery Licensing Manager at LEO Pharma where he was responsible for preclinical stage licensing and out-sourcing. During his tenure, Bobby was instrumental in designing and implementing LEO Pharma's drug discovery out-sourcing strategy. Before then, Bobby was a Project Leader and Principal Scientist at Maxygen ApS.Bobby serves on the Board of Directors of the biotech companies Acesion Pharma (Chairman), Concit Pharma and C10 Pharma.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 95%
Last updated:
For AI agents: llms.txt
Industries Bobby Soni invests in
Stages Bobby Soni invests in
Countries Bobby Soni invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 21 (53%)
- Medical 10 (25%)
- Health Care 9 (23%)
- Therapeutics 5 (13%)
- Medical Device 5 (13%)
Stage
- Convertible Note 21 (53%)
- Pre-Seed 10 (25%)
- Debt Financing 4 (10%)
- Seed 2 (5%)
- Series A 1 (3%)
Country
- Denmark 22 (55%)
- Germany 2 (5%)
- Switzerland 2 (5%)
- The Netherlands 2 (5%)
- Norway 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| First-in-class hardware-and-software-as-a-service diagnostics for the 400M suffering from middle ear problems | $530K / Pre-Seed / Feb 28, 2024 | ||
| Solid Therapeutics develops novel cancer therapeutics with dual performance targeting cancer cells and immune cells to treat solid tumors. | Convertible Note / Sep 05, 2023 | ||
| HHC Medical is a health tech company developing targeted non-invasive drug delivery devices through electroporation to transfect a large number of cells. It was founded in 2019 and is headquartered in Hillerød, Denmark. | Convertible Note / Sep 05, 2023 | ||
| FimmCyte develops a novel disease modifying treatments for fibro-inflammatory diseases, starting with Endometriosis. | Sep 05, 2023 | ||
| TriptoBIO is a biotechnology research company developing a platform for producing natural plant compounds. Its platform utilizes synthetic biology techniques to produce a class of plant compounds, called diterpenoids, through fermentation, allowing novel applications of plant diterpenoids while avoiding intensive plant farming and petrochemicals. | $539.6K / Convertible Note / Sep 04, 2023 | ||
| Rapidemic develops a molecular point-of-care test for the diagnosis of sexually transmitted infections. Their proprietary technology increases the sensitivity and specificity of the reaction while keeping manipulations to a minimum. Its technology enables low-temperature diagnostics while safeguarding accuracy and reducing false positives. | $549K / Convertible Note / Aug 31, 2023 | ||
BioHalo
|
BioHalo is transforming the halogenated chemicals industry by developing more sustainable and bio-based fluorinated polymers and high-performance materials. | $542.1K / Convertible Note / Aug 31, 2023 | |
| Amalus Therapeuticss' objective is to significantly improve the lives of those suffering from cancer and fibrotic disorders. | $542.1K / Convertible Note / Aug 31, 2023 | ||
| Leopard Biosciences is democratizing diagnostics by putting molecular testing power in the hands of doctors and patients at the point of treatment. | $549K / Convertible Note / Aug 31, 2023 | ||
| Aiomic is a HealthTech company developing AI-enhanced reporting and prediction tools to combat postoperative complications. It offers automated tracking and real-time risk assessment using the company's Surgical Advanced Warning (SAW) system that functions as a business intelligence tool for hospitals, a decision support tool for healthcarepractitioners, and an individualized patient empowerment tool by allowing patients to gain insight into their risk profiles. | Convertible Note / Mar 16, 2023 | ||
| See all 40 investments → | |||
Co-Investors
About BioInnovation Institute
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
BioInnovation Institute Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bobby Soni
Chief Business Officer
|
|||
Casper Linnemann Erichsen
Communications lead
|
|||
Maj Hedtjärn
Entrepreneur in Residence
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Bobby Soni invest in?
Bobby Soni invests primarily in Biotechnology, Medical and Health Care startups, most often at Convertible Note and Pre-Seed stage. Most of the 40 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bobby Soni?
Public channels for Bobby Soni include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bobby Soni last invest?
The most recent investment recorded for Bobby Soni closed in Feb 2024. Shizune tracks 40 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
